{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:38:13Z","timestamp":1782362293642,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572979"],"award-info":[{"award-number":["81572979"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0019\/2024\/RIA1"],"award-info":[{"award-number":["0019\/2024\/RIA1"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ajps.2025.101020","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T02:49:05Z","timestamp":1736477345000},"page":"101020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["IL-2-loaded liposomes modified with sorafenib derivative exert a synergistic anti-melanoma effect via improving tumor immune microenvironment and enhancing antiangiogenic activity"],"prefix":"10.1016","volume":"20","author":[{"given":"Xuan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kudelaidi","family":"Kuerban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jajun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danjie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Zhun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10400","key":"10.1016\/j.ajps.2025.101020_bib0001","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ajps.2025.101020_bib0002","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent advances in the treatment of melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajps.2025.101020_bib0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-017-02251-3","article-title":"Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ajps.2025.101020_bib0004","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.ajps.2025.101020_bib0005","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1681869","article-title":"TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity","volume":"9","author":"Lee","year":"2020","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.ajps.2025.101020_bib0006","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.ajps.2025.101020_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004991","article-title":"TransCon IL-2 \u03b2\/\u03b3: a novel long-acting prodrug with sustained release of an IL-2R\u03b2\/\u03b3-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer","volume":"10","author":"Rosen","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"201","key":"10.1016\/j.ajps.2025.101020_bib0008","doi-asserted-by":"crossref","first-page":"201ra118","DOI":"10.1126\/scitranslmed.3006221","article-title":"Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia","volume":"5","author":"Gutbrodt","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ajps.2025.101020_bib0009","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","article-title":"Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies","volume":"22","author":"Muhammad","year":"2023","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.ajps.2025.101020_bib0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jaad.2021.09.075","article-title":"Melanoma: an update on systemic therapies","volume":"86","author":"Skudalski","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.ajps.2025.101020_bib0011","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00262-008-0455-z","article-title":"Local therapy of cancer with free IL-2","volume":"57","author":"Den Otter","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"17","key":"10.1016\/j.ajps.2025.101020_bib0012","doi-asserted-by":"crossref","first-page":"17554","DOI":"10.1021\/acsnano.3c06733","article-title":"Enhanced local delivery of engineered IL-2 mRNA by porous silica nanoparticles to promote effective antitumor immunity","volume":"17","author":"Shin","year":"2023","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.ajps.2025.101020_bib0013","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1007\/s00253-013-5349-0","article-title":"Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo","volume":"98","author":"Ye","year":"2014","journal-title":"Appl Microbiol Biotechnol"},{"issue":"7","key":"10.1016\/j.ajps.2025.101020_bib0014","doi-asserted-by":"crossref","first-page":"6996","DOI":"10.1021\/acsnano.5b01326","article-title":"Surface functionalization of nanoparticles with polyethylene glycol: effects on protein adsorption and cellular uptake","volume":"9","author":"Pelaz","year":"2015","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.ajps.2025.101020_bib0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","article-title":"Interleukin-2: biology, design and application","volume":"36","author":"Arenas-Ramirez","year":"2015","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.ajps.2025.101020_bib0016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13046-021-02208-x","article-title":"Epigenetic regulation of ferroptosis via ETS1\/miR-23a-3p\/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma","volume":"41","author":"Lu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ajps.2025.101020_bib0017","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.ajps.2025.101020_bib0018","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1093\/annonc\/mdt375","article-title":"Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial","volume":"24","author":"Procopio","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ajps.2025.101020_bib0019","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/CJI.0000000000000023","article-title":"A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma","volume":"37","author":"Monk","year":"2014","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.ajps.2025.101020_bib0020","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1038\/s41467-019-11782-w","article-title":"A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control","volume":"10","author":"Sun","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajps.2025.101020_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.991052","article-title":"Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: mechanistic insights","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.ajps.2025.101020_bib0022","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41419-023-06354-2","article-title":"The duality of CXCR3 in glioblastoma: unveiling autocrine and paracrine mechanisms for novel therapeutic approaches","volume":"14","author":"Chan","year":"2023","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.ajps.2025.101020_bib0023","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/molecules25030573","article-title":"Introduction of mercaptoethyl at sorafenib pyridine-2-amide motif as a potentially effective chain to further get sorafenib-PEG-DGL","volume":"25","author":"Wang","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.ajps.2025.101020_bib0024","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s13402-022-00667-8","article-title":"Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy","volume":"45","author":"Mortezaee","year":"2022","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"10.1016\/j.ajps.2025.101020_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting macrophages in cancer immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.ajps.2025.101020_bib0026","article-title":"An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2","volume":"4","author":"Silver","year":"2023","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.ajps.2025.101020_bib0027","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ijc.28362","article-title":"Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity","volume":"134","author":"Chen","year":"2014","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.ajps.2025.101020_bib0028","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.ajps.2025.101020_bib0029","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.ajps.2025.101020_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.616837","article-title":"Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment","volume":"12","author":"Bourhis","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ajps.2025.101020_bib0031","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41419-024-06493-0","article-title":"Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer","volume":"15","author":"Xie","year":"2024","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.ajps.2025.101020_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002460","article-title":"IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors","volume":"9","author":"Beyranvand Nejad","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ajps.2025.101020_bib0033","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.1038\/s41598-017-12414-3","article-title":"The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis","volume":"7","author":"Enomoto","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ajps.2025.101020_bib0034","first-page":"825","article-title":"CXCR3 confers sorafenib resistance of HCC cells through regulating metabolic alteration and AMPK pathway","volume":"12","author":"Ren","year":"2020","journal-title":"Am J Transl Res"},{"issue":"1","key":"10.1016\/j.ajps.2025.101020_bib0035","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.ajps.2025.101020_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188754","article-title":"Targeting EGFR in melanoma\u2014the sea of possibilities to overcome drug resistance","volume":"1877","author":"Pastwi\u0144ska","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.ajps.2025.101020_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106789","article-title":"Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15\/EGFR complex","volume":"192","author":"Gu","year":"2023","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.ajps.2025.101020_bib0038","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41419-020-2413-4","article-title":"miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR","volume":"11","author":"Ji","year":"2020","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.ajps.2025.101020_bib0039","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/aps.2017.5","article-title":"New knowledge of the mechanisms of sorafenib resistance in liver cancer","volume":"38","author":"Zhu","year":"2017","journal-title":"Acta Pharmacol Sin"}],"container-title":["Asian Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087625000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087625000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:40:31Z","timestamp":1778827231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1818087625000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1818087625000066"],"URL":"https:\/\/doi.org\/10.1016\/j.ajps.2025.101020","relation":{},"ISSN":["1818-0876"],"issn-type":[{"value":"1818-0876","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-2-loaded liposomes modified with sorafenib derivative exert a synergistic anti-melanoma effect via improving tumor immune microenvironment and enhancing antiangiogenic activity","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajps.2025.101020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Shenyang Pharmaceutical University. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101020"}}